Wall Street Zen Upgrades Adlai Nortye (NASDAQ:ANL) to Hold

Adlai Nortye (NASDAQ:ANL) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Other analysts have also issued reports about the company. HC Wainwright raised Adlai Nortye from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Friday, February 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Adlai Nortye has an average rating of “Hold” and a consensus price target of $16.00.

Adlai Nortye Stock Down 3.6%

NASDAQ:ANL opened at $8.91 on Friday. The stock’s 50-day simple moving average is $5.93 and its 200 day simple moving average is $3.09. Adlai Nortye has a twelve month low of $0.88 and a twelve month high of $12.09.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.